Internal Medicine, Nephrology · McAllen, TX
NPI
1265849442
Since 2014
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
409 Lindberg Ave
McAllen, TX, 78501
Phone (956) 682-1508
Groups this clinician bills Medicare through
Medicare paid, 2024
$211K
1,695 services
Medicare patients, 2024
322
Average age 70
Drug cost, 2024
$2.2M
4,478 prescriptions
Company payments, 2025
$1,081
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Franklin D Ponce Herrera was code 90935 (hemodialysis), 341 times for 80 patients. In total Franklin D Ponce Herrera billed 1,695 services in 17 codes, and Medicare paid $211K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 90935 Hemodialysis | Facility | 341 | 80 | $53.69 | $18K |
| 90960 ESRD Related Services (not dialysis) | Office | 312 | 67 | $262.83 | $82K |
| 99232 Hospital E&M - Subsequent | Facility | 225 | 93 | $59.61 | $13K |
| 90961 ESRD Related Services (not dialysis) | Office | 163 | 58 | $213.11 | $35K |
| 99214 Office E&M - Established | Office | 160 | 98 | $62.96 | $10K |
| 99222 Hospital E&M - Initial | Facility | 119 | 86 | $98.93 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 96 | 50 | $89.77 | $8,617 |
| 99213 Office E&M - Established | Office | 95 | 75 | $48.87 | $4,643 |
| 99223 Hospital E&M - Initial | Facility | 70 | 54 | $129.55 | $9,069 |
| 99204 Office E&M - New | Office | 19 | 19 | $119.65 | $2,273 |
| 90962 ESRD Related Services (not dialysis) | Office | 19 | 12 | $152.87 | $2,905 |
By year: 2022 $82K for 1,094 services; 2023 $243K for 1,932 services; 2024 $211K for 1,695 services.
Medicare prescription drug claims, 2024
In 2024, the drug Franklin D Ponce Herrera prescribed most often to Medicare patients was Telmisartan, with 379 prescriptions and refills. In total Franklin D Ponce Herrera wrote 4,478 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Telmisartan Generic | 379 | 1,019 | 156 | $13K |
| Nifedipine Er Nifedipine | 310 | 804 | 123 | $12K |
| Prosol Parenteral Amino Acid 20% No.1 | 287 | 287 | 12 | $55K |
| Ozempic Semaglutide | 249 | 272 | 54 | $250K |
| Sevelamer Carbonate Generic | 231 | 509 | 95 | $65K |
| Veltassa Patiromer Calcium Sorbitex | 180 | 227 | 49 | $201K |
| Velphoro Sucroferric Oxyhydroxide | 175 | 211 | 54 | $484K |
| Lokelma Sodium Zirconium Cyclosilicate | 173 | 271 | 63 | $178K |
| Clinisol Parenteral Amino Acid 15% No.5 | 129 | 129 | Under 11 | $25K |
| Carvedilol Generic | 125 | 325 | 52 | $1,041 |
| Farxiga Dapagliflozin Propanediol | 119 | 265 | 43 | $143K |
| Amlodipine Besylate Generic | 109 | 315 | 51 | $775 |
| Furosemide Generic | 104 | 259 | 56 | $682 |
| Atorvastatin Calcium Generic | 86 | 228 | 33 | $855 |
| Allopurinol Generic | 79 | 209 | 33 | $629 |
Brand drugs: - claims; generic drugs: 2,713 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Franklin D Ponce Herrera $1,081 ($1,081 in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $261.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $261 |
| Akebia Therapeutics Inc AKBA | 7 | $193 |
| Vifor Pharma, Inc. | 12 | $184 |
| Calliditas Therapeutics US Inc. | 4 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $83.82 |
| Novo Nordisk Inc NVO | 3 | $64.1 |
| Fresenius USA Marketing, Inc. | 2 | $49.8 |
| Scpharmaceuticals Inc. SCPH | 1 | $34.63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27.62 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $26.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.